ERBB2 and breast carcinoma: According to the authors, the greatest advantage of targeting the IGF system is its crosstalk with other signalling pathways, as preclinical work has identified significant antitumor activity when IGF-1R is concordantly targeted with mTOR, ERα, the EGF receptor and HER2 in breast cancer.